News Analysis: Wong Chi-huey’s OBI Pharma Sale—The Real Issue Isn't Profit, but the Strategy Behind Selling Only 10 Lots

A critique of Academia Sinica President Wong Chi-huey and his daughter’s sale of OBI Pharma stock. The author argues that the public is missing the point: the focus should be on why the broker suggested selling exactly 10 lots (likely to evade large-shareholder reporting thresholds) and what the long-term pattern of selling reveals about Wong's lack of confidence in the company's future before the unblinding results.